Business Context and Reporting Period
This Form 6-K filing by Universe Pharmaceuticals INC covers the month of December 2021. The report discloses a material corporate governance change: the appointment of Mr. Baochang Liu as Chief Operating Officer, effective December 1, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding executive appointments and does not contain financial statements.
Material Changes
- Executive Appointment: Mr. Baochang Liu was appointed Chief Operating Officer on December 1, 2021.
- Background: Mr. Liu brings over 17 years of pharmaceutical marketing experience, including recent roles as Vice President of Marketing at China Shineway Pharmaceutical Group Ltd. and General Manager of the OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It confirms that Mr. Liu has no family relationship with directors or executive officers and has not been involved in reportable transactions with the Company in the past two years.
Key Facts for Investor Verification
- Verify the effective date of Mr. Liu's appointment (December 1, 2021).
- Confirm Mr. Liu's prior employment history at China Shineway Pharmaceutical Group Ltd. and Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Note that this filing does not include updated financial performance data.